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ABSTRACT  
Background: Newly developed biosimilar agents confer significant cost saving advantages, 
yielding the potential to mitigate rising drug costs and expand patient access to care for important 
biologic therapies. Biosimilar market uptake greatly depends upon healthcare provider willingness 
to promote, prescribe, and use biosimilars in clinical practice. 
Objective: To perform a systematic review evaluating current United States (U.S.) and European 
(EU) health care provider knowledge, perceptions, and prescribing behaviors of biosimilar 
medicines to assess the need for clinician-directed, biosimilar education. 
Methods: An electronic literature search was conducted using journal databases, including 
PubMed, Embase, and Cochrane Library. Terms related to biosimilar agents, survey questionnaires, 
and education were used. Two independent reviewers evaluated 158 citations published from 
January 1, 2014 to March 5, 2018, that were the result of this search. Studies in English were 
included if they surveyed U.S. or EU physician and/or pharmacist knowledge, attitudes, and/or 
prescribing preferences of biosimilar drugs. Overall trends in prescribing behavior and perceptions 
were abstracted.  
Results: A total of 20 studies met inclusion criteria. Three studies originated from the U.S. and 17 
from Europe. Hospital specialists, gastroenterologists, and rheumatologists were the most 
frequently surveyed practitioners. Percent of biosimilar prescribing varied widely between 
countries and within similar practice fields. If used, biosimilars were predominantly prescribed in 
biologic-treatment naïve patients. An overall lack of biosimilar familiarity in both U.S. and EU 
health care settings accompanied concerns about biosimilar safety, efficacy, extrapolation, and 
interchangeability. Detailed descriptions of biosimilar education programs were lacking from the 
literature.  
Conclusions: Findings from this review indicate that U.S. and EU healthcare providers still 
approach biosimilar medicines with caution, citing limited biosimilar knowledge, low prescribing 
comfort, and safety and efficacy concerns as main deterrents for biosimilar use. To realize the full 
cost-saving potential of biosimilar medicines, clinician-directed, biosimilar education will be 
imperative to address gaps in biosimilar knowledge, facilitate prescribing changes, and ultimately 
increase biosimilar use.  
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What is already known about this subject:  
• Patents of key biologic therapies have expired or will lose patent protection by 2020, which 
is driving pharmaceutical manufacturer interest in biosimilar drug development.  
• Cost-effective biosimilar medicines have been shown in Europe to increase patient access to 
care earlier in the therapy cycle, decreasing costs and improving health outcomes for 
patients.  
• Biosimilar use and market uptake are contingent, in part, upon physician and pharmacist 
confidence and willingness to prescribe, promote, and use biosimilar medicines in their 
clinical practice.   
What this study adds: 
• This review evaluated 20 U.S. and EU healthcare provider surveys published from 2014 to 
2017 for data related to providers’ biosimilar prescribing habits, biosimilar knowledge, 
biosimilar safety and efficacy concerns, biosimilar extrapolation and interchangeability 
viewpoints, and exposure to biosimilar educational activities.  
• We found that healthcare providers in the U.S. and EU lack biosimilar familiarity and 
understanding, contributing to safety and efficacy concerns and limited biosimilar 
prescribing.  
• To help promote biosimilar uptake, biosimilar-specific education, directed at healthcare 
providers and key physician stakeholders, will likely help to close the knowledge gap, 
improve confidence in biosimilar medicines, and increase biosimilar prescribing. 
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INTRODUCTION  
 Prescription drug spending in the United States has received a great deal of attention as a 
pathway to potentially cut rising healthcare costs. After several years of slowed growth, 2016 saw a 
5.8% increase in pharmaceutical expenditure across all healthcare sectors, totaling $448.2 billion.1 
Biologic agents account for nearly $2.0 billion in U.S. nonfederal hospital costs, with adalimumab, 
etanercept, and infliximab constituting 3 out of the top 5 most expensive drugs overall.1 These 
agents are tumor necrosis factor alfa (TNF) inhibitors and are important guideline-recommended 
therapies for the treatment of patients with inflammatory rheumatic disease or inflammatory bowel 
disease (IBD) refractory to conventional immunosuppressive treatments.2 The high costs of these 
medications have resulted in the development of biosimilar medications, which may confer 
significant cost saving advantages over biologics, yielding the potential to mitigate rising drug costs and 
expand patient access to important biologic therapies.  
  The Food and Drug Administration (FDA) defines a biosimilar product as highly similar but not 
identical to an already licensed biologic product (also termed reference product or bio-originator) in 
terms of quality, safety, and efficacy.3 As of February 2018, nine biosimilars have received FDA 
approval. Yet, only three have made it to U.S. market.4 In comparison, the European Union (EU) has 
forty-one approved biosimilars and generates the most biosimilar revenue worldwide.5,6 Still, initial 
biosimilar uptake in both economies has been slow.6–8 Slowed biosimilar growth has been attributed to a 
time-consuming approval process marked by regulatory challenges, legal issues, payer policy disparities, 
and clinician concerns.7,9,10  Limited reports have highlighted physician and pharmacist reluctance to 
accept biosimilars as equal to the reference product,7,8,11 but fail to describe what specific biosimilar 
factors contribute to clinician uncertainty.7,8,12 The evolving biosimilar pipeline currently includes over 
800 biosimilar drug candidates in development.13 As more biosimilars seek market entry, understanding 
current clinician attitudes and awareness of biosimilars is important to assess the need for biosimilar 
education, promote utilization, and ultimately, help drive down biologic therapy costs.   
 
METHODOLOGY  
 Search Strategy. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) guidelines were followed throughout this review. Relevant English-language articles indexed 
in PubMed, Embase, and Cochrane Library databases from January 1, 2014 to March 5, 2018 were 
searched on March 7, 2018. In addition, the reference lists of identified publications were hand-searched 
5 
 
and screened for relevance. The search strategy used the following PubMed medical subject headings 
(MESH) terms and text words: biosimilar, biosimilar agent, questionnaire, health survey, attitude, 
education, learning, and drug formulary. Search terms were modified for Embase and Cochrane Library 
according to the capabilities of each database.  
 Review Process.  Search results were imported into Covidence Systemic Review Software 
where two independent reviewers (authors Leonard and Wascovich) screened titles and abstracts for 
relevance. Initial disagreements on which articles were eligible were resolved so both reviewers reached 
consensus on which articles to include for full-text review. Studies were eligible for full-text review if 
they were: 1) a journal article, conference proceeding, poster abstract, or editorial letter; and 2) surveyed 
U.S. or EU physician and/or pharmacist knowledge, attitudes, and/or prescribing preferences of 
biosimilar medicines. The EU is considered the most seasoned users of biosimilars, with use since 
2006.14 In 2016, 9 out of 10 global biosimilar product sales were in the EU.14 Therefore, the EU was 
selected for analysis based on its extent of biosimilar experience, and the U.S. was selected to better 
understand the domestic market U.S. clinicians practice in. Articles were excluded if they focused 
exclusively on budget cost analyses, only surveyed patients, non-prescribing nurses, or other non-
prescribing healthcare providers, were general biosimilar overviews, or were published in a 
language other than English. The resulting full-text copies of all studies considered to be of potential 
relevance were retrieved and screened by one author (author Leonard).  
 Data Collection. Data from included studies was extracted into MS Excel 2016 (Microsoft 
Corporation, Redmond, WA) by 1 of the 2 initial reviewers (author Leonard) and independently 
checked by a second reviewer from among the authors of this study for methodological quality and 
completeness. The following characteristics were retrieved: general information (first author, year 
of publication, country of publication); method (online survey versus semi-structured interview, 
sampling method used, provider type), sample size, response rate, study outcomes, and 
conclusions. 
 In addition, four topics for data extraction were identified, a priori, based on a collaborative 
discussion between study authors (Leonard, Wascovich, Oskouei, Gurz). Relevant experiences of 
these colleagues to the current study include leading national biosimilar strategy on behalf of 
nearly 3800 hospitals and health systems, researching health system stakeholders’ evaluation and 
management of biosimilars, and supporting biosimilar contracting, pharmacy purchasing, and 
procurement. Topics included: (1) clinician biosimilar prescribing behaviors; (2) clinician 
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biosimilar knowledge; (3) biosimilar clinical concerns; (4) biosimilar education programs for 
providers. These topic areas were specifically identified as key areas of unknown knowledge 
through health system stakeholder interviews and surveys, professional conferences, and biosimilar 
manufacturer engagements as related to the study authors’ professional roles.  
Biosimilar prescribing behaviors were categorized as percent of clinicians currently 
prescribing biosimilar medicines) or percent of clinicians willing to prescribe biosimilar medicines. 
Biosimilar knowledge included knowledge of the FDA or European Medicines Agency (EMA) 
definition of a biosimilar medicine or reported familiarity with the concept of biosimilar medicines. 
Clinical concerns included problems expressed relating to biosimilar safety, efficacy, extrapolation, 
or pharmacy-driven substitution. Biosimilar education was categorized as clinicians’ means of 
biosimilar education or clinicians’ biosimilar educational preferences.  
 
RESULTS 
  The searches identified 158 records, which resulted in 138 nonduplicate items. Twenty 
surveys met the inclusion criteria and were included in this systematic review (Figure 1). The 
included studies originated from the United States of America15–17, Belgium18,19, France20–22, 
Germany23,24, Italy25, Ireland26, Malta27, Hungary28, and the United Kingdom (UK)29 (Table 1). 
Five surveys included multiple EU states30–34 (Table 1).  
Biosimilar Prescribing Behaviors. Sixteen studies quantified clinicians’ biosimilar 
prescribing habits.15,17,29–34,19,21–26,28 In Danese et al.30 (EU, 2014), 61% of gastroenterologists felt 
little or no confidence in using biosimilars, 26% felt confident enough, 8% felt very confident, and 
5% felt totally confident. When the survey was repeated one year after biosimilars became 
available in the EU, confidence had increased, as 19.5% of gastroenterologists felt little or no 
confidence in using biosimilars, 33.9% felt confident enough, 17.8% felt very confident, and 28.8% 
felt totally confident (EU, 2016).31 
In Beck et al.21 (France, 2016) and van Overbeeke et al.19 (Belgium, 2016), approximately 
7% of rheumatologists had prescribed at least one biosimilar. In another 2016 French survey, 22% 
of physicians reported writing ≥ 1 biosimilar prescription/week, 30.5% between 6-to-12 biosimilar 
prescriptions/year, and 47% < 6 biosimilar prescriptions/year.22 In Pasina et al.25 (Italy, 2016), 51% 
of clinicians prescribed biosimilars to biologic-naïve patients only, while 25% also prescribed 
biosimilars to patients with previous biologic exposure. Greater than 50% biosimilar prescribing 
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was reported in Hallersten et al.32 (EU, 2016) and Kellner et al.33 (EU, 2016). Kellner et al.33 
identified a general correlation between length of biosimilar exposure and willingness to prescribe 
biosimilars, although specific details of this correlation were not described in the published 
abstract. 
In Narayanan et al.34 (EU, 2016), 60% of rheumatologists reported a high likelihood to 
prescribe biosimilars, but would limit use to a small patient population first. Years of practice 
experience did not significantly effect prescribing preferences; however, a higher proportion (57%) 
of rheumatologists with >20 years of practice experience identified the lack of biosimilar long-term 
data as a key impediment to prescribing.34 Limited biosimilar use in a small, select group of 
patients was also reported by 38% of respondents in Barsell et al.15 (U.S., 2017).  
Biosimilars were still largely considered second-line therapies mainly prescribed for 
biologic-naïve patients. Eighty-eight percent of gastroenterologists in Sullivan et al.23 (Germany, 
2017) and 95% of rheumatologists in Waller et al.24 (Germany, 2017) preferred to prescribe a bio-
originator to a biosimilar as first-line therapy for IBD or rheumatic diseases, respectively. 
Correspondingly, biosimilars only made up 13% and 10% of biologic therapies physicians in 
Sullivan et al.23 and Waller et al.24 prescribed. In Gibofsky et al.17 (U.S., 2017), 66% of 
rheumatologists were only likely to start biosimilar therapy in biologic-treatment naïve 
individuals.17 Specialists also primarily prescribed biosimilars in biologic-treatment naïve patients 
in O’Callaghan et al.26 (Ireland, 2017), Chapman et al.29 (UK, 2017), and Baji et al.28 (Hungary, 
2016).  
Gaps in Biosimilar Knowledge. There was a lack of biosimilar awareness in the EU and U.S.  
In Pasina et al.25 (Italy, 2016), only 22.9% of physicians and 38.8% of pharmacists indicated having 
complete or good knowledge about biosimilars. Likewise, in Cassar et al.27 (Malta, 2016), only 6% of 
physicians were familiar with biosimilarity, 35% had a basic understanding, and 59% could not define 
biosimilars or had never heard of them. Approximately 55% of rheumatologists in Beck et al.21 (France, 
2016) had little knowledge of biosimilars; lack of knowledge was greater amongst office-based 
physicians (23.7%) than hospital-based physicians (61.8%).  
Higher familiarity with biosimilars was reported by 97% of rheumatologists in Kellner et al.33 
(EU, 2016), but only 48% correctly identified the EMA definition of a biosimilar. In Sidikou et al.22 
(France 2016), 61% of physicians reported good biosimilar knowledge and 70% reported a high level of 
confidence for biosimilar use. Only half of respondents had actually prescribed biosimilars at the time of 
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the survey.22 In Barsell et al.15 (U.S., 2017), 62% of dermatologists had a basic understanding of 
biosimilars, 27% reported a complete understanding, and 11% reported that they have never heard of 
biosimilars. Of those who reported having a complete understanding of biosimilars, 21% incorrectly 
described a biosimilar as a generic copy of a biologic molecule.15 Similarly, 21% of participants in 
O’Callaghan et al.26 (Ireland, 2017) mistook biosimilars as generic biologic medicines. More 
pharmacists reported having a higher biosimilar familiarity than general practitioners (75.2% vs. 40.3%, 
p < 0.01).26 Van Overbeeke et al.19 (Belgium, 2017) reported the highest level of biosimilar knowledge 
amongst respondents, at 90%. Per the study, participating rheumatologists had already received 
information on the launch of biosimilars and the patent expirations from “different, well-balanced 
sources.”19 
 In Cohen et al.16 (U.S., 2016), 55% of rheumatologists and 32.8% of gastroenterologists were 
unaware that biosimilar Filgrastim was marketed and available for use. More recently in Gibofsky et 
al.17 (U.S., 2017), 84% of rheumatologists knew about biosimilar infliximab’s approval, but only 47% 
and 34% knew about the respective biosimilar adalimumab and biosimilar etanercept approvals. In 
Chapman et al.29 (UK, 2017), 75% of clinicians were aware that biosimilars were available on their local 
formulary.  
Clinical Concerns. Clinicians were hesitant about biosimilar safety, efficacy, extrapolation, and 
pharmacy-driven substitution. Most safety concerns regarded immunogenicity, or the propensity of the 
biosimilar to generate an immune response to itself and other related proteins.35 In Pasina et al.25 (Italy, 
2016), 23% of respondents believed biosimilars had a higher immunogenicity risk than bio-originators, 
with poor-quality approval trials. Greater than 60% of physicians in Barsell et al.15 (U.S., 2017), Cohen 
et al.16 (U.S., 2016), Beck et al.21 (France, 2016), O’Callaghan et al.26 (Ireland, 2017), and Danese et 
al.30 (EU, 2014) were also concerned about biosimilar immunogenicity. Immunogenicity concerns 
decreased from 67% to 27.1% in Danese et al.31 (EU, 2016), over a two-year period.  
Providers doubted biosimilar safety and efficacy in extrapolated indications. Indication 
extrapolation refers to the approval of a biosimilar for indications held by the bio-originator, but were 
not directly evaluated during the biosimilar’s clinical trials. Approximately 39% of rheumatologists in 
van Overbeeke et al.19 (Belgium, 2017) and 64% of pharmacists in Adé et al.20 (France, 2017) opposed 
indication extrapolation. In Danese et al.31 (EU, 2016), 32.2% of gastroenterologists opposed 
extrapolation across other specialty (e.g., rheumatic) indications and 25% opposed extrapolation across 
IBD. In Baji et al.28 (Hungary, 2016), 65% of clinicians had concerns about biosimilar use in Crohn’s 
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disease (efficacy, n = 2; safety, n = 7; efficacy and safety, n = 21); 12% opposed biosimilar use 
altogether due to the lack of evidence from randomized controlled trials in this indication. Physicians in 
Beck et al.21 (France, 2016) cited the most common barriers to biosimilar use as extrapolation of 
efficacy and safety to all indications of the bio-originator (67.2%), and the lack of long-term tolerability 
data (66.1%). 
Interchangeability and pharmacy-led switching also incited provider concerns. An 
interchangeable biosimilar, by definition, is expected to produce the same clinical result as the reference 
product in any given patient; some U.S. state laws allow an interchangeable biosimilar to be substituted 
for the reference product at the pharmacy level, without notifying the patient’s physician. In Danese et 
al.31 (EU, 2016), only 44% of respondents considered biosimilars interchangeable (improved from 6% 
noted in Danese et al.30), while 39.9% did not, due to insufficient data supporting interchangeability. 
Furthermore, 89.8% disagreed with pharmacy-driven automatic substitution of the bio-originator with a 
biosimilar.31 Similar beliefs were noted in Barsell et al.15 (U.S., 2017), Cassar et al.27 (Malta, 2016), and 
O’Callaghan et al.26 (Ireland, 2017). In O’Callaghan et al.26, 61% of physicians and 58% of pharmacists 
believed switching should solely be the prescriber’s decision. In Adé et al.20 (France, 2017), 95% of 
pharmacists believed interchanging biosimilars for bio-originators was a joint physician-pharmacist 
responsibility.  
In Cohen et al.16 (U.S., 2016), 80% of respondents were unaware that interchangeability could 
enable pharmacist-led switching. A later U.S. survey conducted by Gibofsky et al.17 (U.S., 2017), found 
that 71% of rheumatologists were knowledgeable about interchangeability, and 74 indicated an 
interchangeable designation would be very or moderately important. Positive attitudes about 
interchangeability were also noted in Chapman et al.29 (UK, 2017), in which > 90% of physicians had no 
or minor safety or efficacy concerns when switching patients. 
Biosimilar Education Programs for Providers. Self-study and peer-reviewed 
journals/professional guidelines were the two primarily trusted sources of biosimilar information in both 
the U.S. and EU.16,18,21,26,32 Discussion with physician and pharmacist colleagues was also a reliable 
mean of biosimilar information.16,21 Additional sources of biosimilar education included manufacturer 
promotional materials, continuing education programs, and conference/seminar attendance.19,21,26 
O’Callaghan et al.26 (Ireland, 2017) uniquely found that pharmacists (44%) were more likely than 
medical specialists (13%) and general practitioners (7%) to consult manufacturer promotional materials 
to learn more about the biosimilar product. Danese et al.31 (EU, 2016) was the only survey to grade 
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biosimilar educational activities. Overall, gastroenterologists found biosimilar educational activities 
favorable (56%), unnecessary (16%), too confusing (15%), or too optimistic about safety and efficacy 
(13%).31 The exact ‘educational activities’ were not defined.31 
 
DISCUSSION 
 To our knowledge, this is the first systematic review designed to assess health care practitioner 
understanding, perceptions, and prescribing culture of biosimilar medicines through 2017. Most 
reviewed studies were set outside of the United States (85%) and primarily surveyed gastroenterologists, 
rheumatologists, and specialty physicians who routinely prescribed bio-originators in clinical practice. 
While this review also included pharmacists, only 4 studies evaluated pharmacists perspectives.18,20,26,29 
 Overall, biosimilar prescribing rates varied between country and amongst practitioner type. In a 
2015 French survey, for example, 7% of rheumatologists prescribed biosimilars.21 In a second French 
study (survey year not available), nearly 99% of physicians wrote more than 1 biosimilar 
prescription/year.22 In nearby Germany, biosimilars made up approximately 13% of the biologic 
therapies gastroenterologists prescribed23 and approximately 10% of biologic therapies rheumatologists 
prescribed24, demonstrating limited biosimilar uptake. In comparison, 72% of rheumatologists in Kellner 
et al.33 (EU, 2016) reported prescribing biosimilar infliximab to at least one patient. A positive trend 
towards increasing length of biosimilar exposure and willingness to prescribe biosimilars was reported 
by two studies, suggesting that time and experience favorably effect biosimilar prescribing behavior.31,33 
 This review also identified gaps in biosimilar knowledge and understanding amongst clinicians. 
The majority of surveyed physicians indicated having an incomplete or basic awareness of biosimilar 
medicines, with familiarity higher amongst hospital-based than office-based practitioners.16,21,25–27 
Pharmacists, on average, indicated having a higher level of biosimilar familiarity than physicians.18,25,26 
Of physicians who reported having a high familiarity with biosimilars in Kellner et al.33 (EU, 2016) and 
Barsell et al.15 (U.S., 2017), approximately 48% and 21%, respectively, incorrectly defined 
biosimilarity, highlighting a discrepancy between claimed biosimilar knowledge and actual awareness. 
In Cohen et al.16 (U.S, 2016) and Gibofsky et al.17 (U.S., 2017), greater than 50% of U.S. physicians 
were unaware of the most recent U.S. biosimilar approvals; this lack of awareness likely contributes to 
decreased biosimilar prescribing and uptake in the U.S.  
 Notably, both U.S. and EU clinicians seemed to be unaware of the existence of biosimilars as 
alternative safe and effective treatment options for their patients. Most physicians perceived biosimilar 
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medicines as second or third-line treatment options in patients requiring biologic therapy, and restricted 
use to biologic-treatment naïve patients only.17,23–26,28,29 Underlying safety (particularly, 
immunogenicity) and efficacy concerns deterred most physicians from switching patients already 
tolerating sustained bio-originator therapy to the biosimilar agent.14,15,16,20,24–29,30 Furthermore, the lack 
of long-term tolerability data and lack of biosimilar data altogether in extrapolated indications evoked 
considerable concern, curtailing biosimilar prescribing and uptake.19–21,28,31 
 Means of health care provider biosimilar education were vaguely described. Self-instruction and 
independent guideline and/or journal article review were the most common learning methods, followed 
by colleague discussion, continuing education, and consulting promotional manufacturer 
material.16,18,19,21,26,32 Importantly, physicians who received information on the launch of biosimilars and 
biologic patent expirations in Van Overbeeke et al.19 (Belgium, 2017) reported the highest level of 
biosimilar knowledge amongst all survey respondents, at 90%. Although the exact means of biosimilar 
education were not reported, Van Overbeeke et al.19 suggests a positive relationship between biosimilar 
education and biosimilar knowledge. Irrespective of the method, our review indicates a strong need for 
clinician-directed biosimilar education to strengthen biosimilar familiarity, augment understanding, and 
promote acceptance of biosimilar medications as safe and effective treatment options for patients.   
 Biosimilar education should address the key areas of provider concern identified in this review: 
immunogenicity, clinical trial evidence, extrapolation, and interchangeability. Since the reviewed 
surveys were conducted, newer data has emerged supporting biosimilar switching.36,37  Education 
detailing the key findings and implications of these recently published studies will likely facilitate 
understanding and inform policies that govern biosimilar use. Per an AMCP Partnership Forum, 
biosimilar education should also address biosimilar pharmacokinetics and pharmacodynamics and 
medical billing/electronic health record documentation processes.38 The AMCP Forum further 
recommends developing novel educational tools (e.g. online webinars) to supplement traditional 
educational methods (e.g., policy statements, white papers, e-Dossiers).38 
Only two publications have directly explored the effects of biosimilar education on clinician 
attitudes and/or prescribing habits. Per results presented by Murphy et al.39 (UK, 2017) at a conference, 
Cancer Vanguard implemented twelve biosimilar training sessions to oncology staff from January to 
April 2017. Prior to training, 86% of nurses and 43% of doctors had not heard of the term 
“biosimilar/biosimilarity” in the preceding month, and 40.1% of participants were unsure if biosimilars 
would yield the same efficacy response as originator biologics.39 After training, participants’ confidence 
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in using biosimilars grew from mean (SD) scores of 3.1 (3.2) to 7.1 (2.1) (p < 0.001) and 95% believed 
biosimilars had the same efficacy as bio-originators.39  Thus, Murphy et al.39 presented preliminary 
results demonstrating a structured biosimilar educational program’s ability to improve provider 
biosimilar confidence.  
Trotta et al.40 (Italy, 2017) compared prescribing patterns of granulocyte colony-stimulating 
factor (G-CSF) biosimilars pre- and post-implementation of a biosimilar working group formed in May 
2015 to promote the rational and appropriate use of biosimilars. The group developed evidence-based 
guidelines and recommended cost-effective approaches for biosimilar G-CSF procurement and 
prescribing. A pre-post analysis showed that Filgrastim biosimilar use increased from 34.4% to 49.8% 
seven months after the intervention’s implementation (p < 0.0001).40 This study was the first to 
demonstrate that sharing biosimilar information with clinicians yielded significant changes in 
prescribing behavior. Biosimilar education, therefore, not only improves provider understanding and 
confidence, but also elicits actual prescribing change and increases biosimilar use.  
  
LIMITATIONS  
This study has several limitations. First, only one individual screened full-text articles for 
inclusion and extracted data. A second individual then reviewed the extracted data for accuracy and 
completeness, but did not separately extract data from each study. This process potentially introduced 
bias in how results were reported. Second, most of the included articles had design limitations, including 
unreported response rates, small and highly varied sample sizes, and non-validated questionnaires. 
Sampling methods were rarely reported; thus, samples may not have been representative of the entire 
population. Third, the reviewed surveys were conducted at varying time points, in different countries 
with differing laws and policies. No statistical methods were used in this review to correlate survey 
results. Instead, overall trends in the literature were noted. As biosimilar market uptake is a time-
sensitive matter, healthcare provider perceptions of biosimilars may have since evolved over time, and 
likely continue to evolve over time. 
 
CONCLUSIONS 
Findings from this study indicate that clinicians in the U.S. and the EU are cautious about 
biosimilar use and do not predominantly support the use of biosimilars as safe and effective 
treatment options in patients already receiving bio-originator therapy. Provider hesitancies deter 
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biosimilar prescribing and use. Biosimilar education can help to increase prescriber comfort and 
familiarity with biosimilar medicines, inspire prescribing changes, and ultimately drive biosimilar 
utilization. Yet, biosimilar-specific education remains a relatively neglected area of emphasis in the 
published literature. This review identifies several topics that clinician-tailored, biosimilar 
education should address to alleviate existing misunderstandings and bridge knowledge gaps 
altogether. Major areas of focus include thoroughly reviewing the concepts of immunogenicity, 
extrapolation, and interchangeability. Future research should explore different healthcare provider types 
in greater detail and evaluate practitioners’ engagements with patients, to ensure providers can 
effectively communicate with their patients about biosimilars as a treatment option. A mixed-methods 
study including exploratory semi-structured qualitative interviews and a quantitative survey assessment 
of U.S. and/or EU clinicians should be conducted to assess perceived biosimilar educational needs.  
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APPENDIX 
Figure 1: Flow Diagram of Article Selection Process.   
 
Records identified through 
database/reference searching 
(n = 158) 
Abstracts/titles screened 
(n = 138) 
Abstracts excluded, with reasons  
(n = 97) 
-Duplicates: 20  
-Biosimilar Review Article: 26 
-Non-U.S. or EU study: 13 
-Study design (does not evaluate 
healthcare provider perception of 
biosimilar medicines): 15 
-Economic analysis: 25 
Full-text articles assessed 
for eligibility 
(n = 41) 
Full-text articles excluded, with 
reasons 
 (n = 21) 
-Duplicates: 2 
-Non-U.S. or EU study: 1  
-Study design (does not evaluate 
healthcare provider perception of 
biosimilar medicines): 17 
-Full text not in English: 1 
Studies included in 
review 
(n = 20) 
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Table 1: Summary of key information from articles that met inclusion criteria 
Author, 
country, 
journal 
Study Description Objective Outcomes Main Limitations 
Adé et al.20 
France,  
Ann Pharm 
Fra 
2017 
Sample size: 88  
Response rate: 
34%  
Methods: online 
survey 
Sampling: 
convenience  
Sample: 
pharmacists  
Date: 6/23/16-
7/7/17 
 
To assess 
pharmacists’ 
knowledge and 
views of 
biosimilars in 
France and 
Quebec  
[1] 26% of French respondents did not 
receive specific biosimilar training 
[2] Majority lacked knowledge of 
biosimilar development processes 
[3] Only 36% of pharmacists were 
comfortable with biosimilar 
extrapolation to all indications 
approved for the originator product 
Greater than 50% 
of respondents were 
interns in training  
Baji et al.28 
Hungary 
Scand J 
Gastroentero
l.  
2016 
Sample size: 51 
Response rate: N/A 
Methods: 
questionnaire 
Sampling: N/A 
Sample: 
gastroenterologists 
Date: 05/2014 
 
To assess 
gastroenterologis
ts’ preferences 
for bio-
originator vs. 
biosimilar 
treatment in 
Crohn’s Disease 
(CD) 
 
[1] 65% reported safety and/or efficacy 
concerns about biosimilar use in CD 
patients  
[2] Physicians preferred to select the 
reference product over the biosimilar 
60% of the time in biological-naïve 
patients & 74% of the time in patients 
already treated with the bio-originator  
 
Sample selection 
bias; Since May 
2014 in Hungary, 
newly started 
infliximab therapy 
must be undertaken 
with a biosimilar 
antibody 
Barsell et 
al.15  
USA 
J Drugs 
Dermatol 
2017 
 
Sample size: 97 
Response rate: N/A 
Methods: online 
survey 
Sampling: N/A 
Sample: 
dermatologists  
Date: 01/2015-
04/2015 
To assess US 
dermatologists’ 
knowledge and 
awareness of 
biosimilars 
[1] 62% described having a basic 
understanding of biosimilars, but could 
not define them  
[2] 84% prescribed biologics in their 
practice. 25% will definitely or highly 
likely prescribe biosimilars; 38% will 
try using biosimilars in a small group of 
patients first 
[3] Physicians familiarized themselves 
with biosimilars via three main 
methods: self-study (35%), scientific 
publications (25%), and 
conferences/seminars (17%) 
[4] Major hesitancies include safety 
(66%), efficacy (71%), immunogenicity 
(63%), & potential for patients to be 
switched from a biologic to a biosimilar 
without clinician knowledge (68%) 
 
Small sample size; 
potential for non-
responder bias  
20 
 
Beck et al.21  
France  
BioDrugs 
2016 
Sample size: 116 
Response rate: N/A 
Sampling: N/A  
Methods: online 
survey 
Sample: 
rheumatologists 
Date: 6/8/15-
8/2/15 
 
To assess French 
rheumatologist 
knowledge, 
experience, and 
opinions of 
biosimilar 
medicines and 
identify factors 
to promote 
biosimilar 
prescribing 
[1] Only 7% of rheumatologists had 
already prescribed biosimilars  
[2] 67% of respondents did not feel 
comfortable with biosimilar 
extrapolation to all indications of the 
reference medicinal product 
[3] 89% would initiate biosimilar 
therapy in biologic treatment-naïve 
patients  
[4] Only 25% would switch from 
originator to biosimilar in patients 
responding well to bio-originator 
therapy  
[5] 98.3% of participants had ≥ 1 
remaining question about biosimilar 
medicines 
 
Biosimilar 
infliximab was the 
only biosimilar 
medicine available 
in rheumatology at 
the time survey was 
conducted; study 
reflects knowledge, 
experience, & 
opinions of 4.5% of 
French 
rheumatologists 
(116 out of 2598 
rheumatologists in 
France in 2014) 
Cassar et 
al.27  
Malta  
Ann Rheum 
Dis 
2016 
Sample size: 132 
Response Rate: 
14% 
Sampling: N/A  
Methods: online 
survey 
Sample: physicians 
Date: N/A  
To assess 
Maltese 
clinicians’ 
perceptions of 
biosimilars  
[1] 59% of respondents could not define 
biosimilars or had never heard of them 
[2] Only 36% believed reference 
products & biosimilars safely yield the 
same results 
[3] Only 27% of physicians agree that 
patients can be safely switched between 
products during treatment; 46% believe 
it is critical physicians have the sole 
authority over switching 
 
Survey date not 
reported in abstract  
Chapman et 
al.29  
United 
Kingdom  
BMJ Open  
2017 
Sample size: 234 
Response Rate: 
N/A 
Sampling: N/A  
Methods: online 
survey  
Sample: specialty 
physicians, 
pharmacists, nurses  
Date: 08/01/16-
01/08/16 
To compare 
healthcare 
professionals’ 
knowledge, 
attitudes, and 
utilization of 
infliximab and 
insulin glargine 
biosimilars 
[1] 93% of gastroenterologists & 90% 
of rheumatologists reported no or minor 
safety/efficacy concerns when initiating 
biosimilar therapy for biologic-naïve 
patients 
[2] Rheumatologists had major 
concerns about safety (53%) & efficacy 
(55%) when switching patient from bio-
originator to biosimilar 
[3] Gastroenterologists prescribed 
biosimilar infliximab (62%) more than 
rheumatologists (39%) in 2016.  
[4] Most respondents weighted NICE 
guidance and pharmacovigilance 
studies as factors likely to increase their 
use of biosimilars 
 
Estimated low 
response rate 
around 10% 
21 
 
Cohen et 
al.16  
USA 
Adv Ther 
2016 
Sample size: 1201 
Response rate: N/A 
Sampling: N/A 
Methods: survey  
Sample: specialty 
physicians 
Date: 11/20/15-
1/4/16 
 
To assess US 
specialty 
physicians’ 
baseline 
knowledge, 
awareness, and 
perceptions of 
biosimilar drugs 
[1] Physician knowledge about 
biosimilar development process & 
totality of evidence was low 
[2] Only 12% comfortable with 
biosimilar extrapolation 
[3] 55.2% of respondents were unsure 
or concerned about biosimilar safety, 
particularly rheumatologists & 
dermatologists  
[4] Most physicians interested in 
learning more about biosimilar concepts 
from trusted sources: journals, peer 
physicians, congress/symposia 
 
Only one biosimilar 
was approved & 
marketed in the 
U.S. at the time of 
the survey 
Danese et 
al.30 
Europe  
J Crohns 
Colitis  
2014 
Sample size: 307 
Response rate: N/A 
Sampling: N/A 
Methods: online 
survey 
Sample: 
gastroenterologists  
Date: 10/20/13-
11/30/13 
To evaluate 
gastroenterologis
ts’ awareness of 
biosimilar 
monoclonal 
antibodies 
(mAb) & their 
readiness to 
prescribe these 
therapies 
[1] 25% highly confident about 
biosimilar safety/efficacy when 
initiating treatment in biologic-naïve 
patients 
[2] 71% would not switch patients in 
prolonged remission with an originator 
mAb to a biosimilar mAb (lack of 
disease-specific interchangeability 
evidence, immunogenicity concerns) 
[3] 24% comfortable with biosimilar 
extrapolation to all originator approved 
indications 
[4] Most clinicians believed medical 
societies should provide biosimilar 
information, develop multi-specialty 
practice guidelines, & develop rules on 
biosimilar use  
 
Not reported  
Danese et 
al.31  
Europe  
J Crohns 
Colitis 
2016 
Sample size: 118 
Response rate: N/A 
Sampling: N/A 
Methods: online 
survey 
Sample: 
gastroenterologists  
Date: 06/01/15-
11/30/15 
To assess ECCO 
members’ 
evolving views 
of biosimilar 
medicines after 
the introduction 
of biosimilar 
infliximab to 
European 
markets in 2015  
[1] 60% of physicians expressed a high 
confidence level in biosimilar safety & 
efficacy when initiating treatment in 
biologic-naïve patients 
[2] 40% of gastroenterologists would 
not switch a stable patient in prolonged 
remission with an originator mAb to a 
biosimilar mAb 
[3] 51% were comfortable with 
biosimilar extrapolation to all originator 
approved indications 
[4] 56% judged biosimilar educational 
activities were fair & adequate, while 
15% found the education confusing & 
13% found it too optimistic about safety 
and efficacy 
 
Could not guarantee 
same respondents 
between 2013 and 
2015 survey 
 
22 
 
Dylst et al.18 
Belgium  
PharmacoEc
onomics  
2014 
Sample size: 19  
Response rate: 
30% 
Sampling: 
selective  
Methods: semi-
structured 
interviews  
Sample: 
Physicians, 
pharmacists, 
patients, academic, 
industry  
Date: 10/2012-
02/2013  
 
To identify 
biosimilar 
uptake barriers 
in Belgium 
[1] Lack of confidence in biosimilars 
attributed to lack of clinical data 
supporting safe and effective use of 
biosimilars 
[2] Most interviewees believed 
biosimilar prescribing should be 
restricted to biologic-naïve patients 
[3] Originator manufacturing discounts 
exceed the price difference of 
biosimilars, thwarting initiative to 
prescribe 
Interviews 
conducted from 
October 2012-
February 2013. 
Perception of 
originators and 
biosimilars could 
have since evolved 
over time 
 
 
   
Gibofsky et 
al.17  
USA 
Arthritis 
Rheumatol 
2017 
Sample size: 131 
Response rate: 
13.67% 
Sampling: N/A 
Methods: online 
survey 
Sample: 
rheumatologists  
Date: 12/9/16-
12/14/16 
 
To evaluate US 
rheumatologists’ 
familiarity with 
biosimilars and 
the concept of 
biosimilarity   
[1] 99% had prescribed an anti-tumor 
necrosis factor monoclonal antibody 
(TNFα mAB)  
[2] 74% either extremely or moderately 
familiar with FDA’s biosimilar 
definition 
[3] 66% were extremely likely or likely 
to initiate biosimilar therapy in biologic 
treatment-naïve Rheumatoid Arthritis 
patients 
[4] Only 34% were extremely likely or 
likely to initiate biosimilar therapy for 
biologic treatment-naïve patient in an 
extrapolated indication 
[5] 60% unlikely to switch from 
originator to biosimilar in TNFα mAB 
patients doing well, regardless of 
rheumatologic indication 
 
Conference poster 
(not peer-reviewed 
publication) 
Hallersten et 
al.32  
EU5a, 
Poland, 
Sweden  
Regul 
Toxicol 
Pharmacol 
2016 
Sample size: 210 
Response rate: 
22.8% 
Sampling: N/A 
Methods: online 
survey  
Sample: specialty 
physicians  
Date: 04/2015 
 
To explore 
physicians’ 
preferences for 
the content of 
the EU 
biosimilar label 
 
[1] 59% had already prescribed a 
biosimilar  
[2] Physicians refer to peer-reviewed 
journals, professional guidelines, & 
prescription labels (>90% for all three) 
for biological product information  
[3] Majority of respondents expressed 
need to learn more about the origin of 
the clinical data & the distinction of 
adverse events by class and individual 
product 
 
Not reported 
23 
 
Kellner et 
al.33  
Europe 
Ann Rheum 
Dis 
2016 
Sample size: 222 
Response rate: N/A 
Sampling: N/A  
Methods: online 
survey 
Sample: 
rheumatologists 
Date: 06/2016-
08/2015 
 
To assess 
perspectives, 
knowledge, & 
prescribing 
comfort of 
biosimilar 
medicines   
[1] 97% of rheumatologists indicated 
being familiar or very familiar with 
biosimilars, yet only 48% identified the 
correct EMA biosimilar definition 
[2] 65% cited limited or no knowledge 
of biologic development processes  
[3] Average comfort level in 
prescribing biosimilars = 6.5 on scale of 
1 to 10 (10 = extremely comfortable) 
[4] Most rheumatologists preferred to 
prescribe biosimilar in biologic 
treatment-naïve patients or those who 
stopped responding to current biologic 
therapy 
 
Conference abstract 
only available 
Narayanan 
et al.34  
EU5a 
Clin Exp 
Rheumatol 
2016 
Sample size: 100  
Response rate: 
35% 
Sampling: N/A 
Methods: online 
survey  
Sample: 
rheumatologists  
Date: 04/2013-
05/2013 
 
 
To assess the 
factors 
underlying 
rheumatologists’ 
perceptions of 
biosimilars for 
managing 
Rheumatoid 
Arthritis  
[1] 60% doubted similarity to the 
reference product, 53% questioned 
biosimilar safety & efficacy data 
[2] Despite this, 60% reported they 
would definitely/be highly likely to 
prescribe a biosimilar in an eligible 
Rheumatoid Arthritis patient 
[3] 60% would try using biosimilars for 
1-2 years among a small group of 
patients before expanding practice use 
[4] Years of practice experience had no 
effect on physician perceptions & 
willingness to prescribe biosimilars, 
although more physicians with >20 
years of experience identified lack of 
long-term data as a key issue impeding 
biosimilar prescribing 
 
Small sample size 
O’Callaghan 
et al.26  
Ireland  
Regul 
Toxicol 
Pharmacol. 
2017  
 
Sample size: 143 
pharmacists, 377 
physicians 
Response rate: 
72% pharmacists, 
9% physicians 
Sampling: N/A 
Methods: online 
survey 
Target group: 
physicians, 
community 
pharmacists 
Date: 04/2016-
05/2016 
To evaluate 
medical 
specialists’, 
general 
practitioners’, 
and community 
pharmacists’ 
awareness and 
attitudes to 
biosimilars 
[1] Pharmacists (75.2%) & medical 
specialists (85.3%) were more familiar 
with biosimilars than general 
practitioners (40.3%) 
[2] 21% of clinicians mistook a 
biosimilar as the same as a generic 
medicine 
[3] 67% would prescribe a biosimilar in 
treatment-naïve patients; only 28% 
would switch from an originator 
medicine to a biosimilar when a patient 
is clinically stable 
[4] Pharmacists referred to medical 
information from the manufacturer 
(44%) more so than medical specialists 
(17%) and general practitioners (7%) to 
learn details about biologic/biosimilar 
medicines 
 
Selection bias; 
response rates 
varied between 
pharmacists, 
medical specialists, 
and general 
practitioners; 
hospital 
pharmacists not 
represented in the 
study 
24 
 
Pasina et 
al.25  
Italy  
Eur J Med 
2016 
Sample size: 579 
(214 specialists for 
survey, 36 hospital 
pharmacists)  
Response rate: N/A 
Sampling: N/A 
Methods: online 
survey  
Sample: specialty 
physicians, 
hospital 
pharmacists 
Date: 04/01/15-
09/30/15 
 
To assess 
hospital 
specialists’ 
attitude to 
prescribing 
biosimilars and 
to collect 
hospital 
specialists’ 
opinions about 
the quality, 
safety, and 
efficacy of 
biosimilars  
 
[1] Only 23% of survey respondents 
expressed complete or good knowledge 
about scientific principles of biosimilars  
[2] 51% prescribed biosimilars only to 
biologic-naïve patients. Only 25% 
would prescribe biosimilars to 
treatment naïve patients and/or patients 
with previous originator exposure 
[3] More clinicians expressed doubts 
about the scientific validity & lack of 
clinical trial data for biosimilar 
indication extrapolation than 
pharmacists (41% vs. 8%) 
[4] Pediatricians and nephrologists cited 
more favorable experiences 
with/opinions of biosimilars than 
gastroenterologists and rheumatologists 
 
Not reported 
Sidikou et 
al.22  
France  
Eur J Hosp 
Pharm Sci 
Pract 
2016 
Sample size: 36 
Response rate: N/A 
Sampling: N/A 
Methods: online 
survey  
Sample: physicians  
Date: not reported  
 
To evaluate 
concerns raised 
about biosimilars 
by the medical 
community in a 
French hospital  
[1] 22% of physicians were regular 
biosimilar prescribers (≥ 1 
prescription/week), 30.5% were 
occasional prescribers (between 6 to 12 
prescriptions/year), and 47% were 
potential prescribers (<6 
prescriptions/year) 
[2] 53% emphasized the lack of high 
level safety evidence for biosimilars 
[3] Physicians expressed concerns 
about biosimilar efficacy, especially in 
extrapolated indications 
 
Conference abstract 
only available  
Sullivan et 
al.23  
Germany  
PLoS ONE 
2017 
Sample size: 25   
Response rate: N/A 
Sampling: N/A 
Methods: online 
survey   
Sample: 
gastroenterologists  
Date: 12/2015-
03/2016 
To evaluate 
gastroenterologis
ts’ willingness to 
prescribe 
biosimilars and 
explore patient 
attitudes to 
biosimilars 
[1] Biosimilars constitute 12-13% of 
biologic drugs physicians prescribe 
[2] Notwithstanding prescribing quotas, 
88% of gastroenterologists would 
prescribe a bio-originator to a 
biosimilar as 1st-line therapy; bio-
originator still preferred for 3rd-line 
therapy in ulcerative colitis (92%) & 
Crohn’s Disease (76%).  
[3] Most physicians would use 
biosimilars when a treatment change is 
required 
 
Only two 
infliximab 
biosimilar 
compounds 
approved at time of 
survey; sample size 
not representative 
of all practicing 
gastroenterologists 
25 
 
van 
Overbeeke 
et al.19  
Belgium  
BioDrugs  
2016 
Sample size: 41  
Response rate: N/A 
Sampling: N/A 
Methods: online 
survey  
Sample: 
rheumatologists 
Date: 01/2016-
03/2016 
To measure the 
current 
comparative 
knowledge and 
perception of 
rheumatologists 
and Belgian RA 
patients 
regarding bio-
originators and 
biosimilars 
[1] Sources of biosimilar physician 
education included manufacturers, 
government bodies, & congress 
[2] Only 7% of rheumatologists had 
prescribed a biosimilar; 60% would 
prescribe a biosimilar in biologic-naïve 
patients only 
[3] Physicians questioned the quality, 
safety, and interchangeability of 
biosimilars more so than RA patients  
[4] Reasons for not prescribing a 
biosimilar included: ‘less studied than 
the originator,’ and ‘no clinical trials 
conducted in the specific indication’ 
 
Small physician 
response rate; 
online survey 
response options 
were limited 
Waller et 
al.24 
Germany  
Patient 
Prefer 
Adherence  
2017 
Sample size: 50  
Response rate: 
18%  
Sampling: N/A 
Methods: online 
survey  
Sample: 
rheumatologists 
Date: 12/2015-
03/2016 
To evaluate if 
rheumatologist 
biologic 
preferences 
match actual 
prescribing 
behavior and 
explore patient 
attitudes to 
biosimilars  
[1] Biosimilars constitute <10% of 
biologic drugs physicians prescribe  
[2] Notwithstanding prescribing quotas, 
95% would prescribe a bio-originator to 
a biosimilar as either 1st- or 2nd-line 
therapy; bio-originator still preferred 
for 3rd-line therapy by 80-92% 
physicians.  
[3] Most physicians would use 
biosimilars when a treatment change is 
required 
 
Small sample size 
Table 1: Key findings of the reviewed studies. 
 aEU5 = United Kingdom, France, Italy, Spain, Germany  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
